[Three Cases of Amrubicin Administration as Second-or Third-Line Chemotherapy for Primary Small Cell Carcinoma of the Prostate].

Small cell carcinoma (SCC) of the prostate has a poor prognosis. We present three cases of primary SCC of the prostate treated with amrubicin as second- or third-line chemotherapy. Case 1 : A 54-year-old male received cisplatin and irinotecan but showed metastatic progression. Amrubicin was initiated as second-line therapy, leading to tumor shrinkage. However, disease progression (PD) occurred in the ninth month, and he passed away 16 months after treatment initiation. Case 2 : An 82-year-old male treated with combined androgen blockade (CAB) later developed pelvic lymph node enlargement, and SCC was diagnosed. He received carboplatin-etoposide and then carboplatin-irinotecan. Amrubicin was given as third-line therapy but showed no significant response. He passed away 24 months after treatment initiation. Case 3 : A 68-year-old male treated with CAB developed M0CRPC and later distant lymph node metastases, confirmed as SCC. He received cisplatin-etoposide and then amrubicin as second-line therapy, achieving a partial response initially but experiencing PD in the fifth month. He passed away 36 months after starting treatment. Amrubicin may be a therapeutic option for primary SCC of the prostate, but achieving prolonged survival remains difficult.